David Risinger
Stock Analyst at Leerink Partners
(3.60)
# 843
Out of 5,090 analysts
172
Total ratings
66.3%
Success rate
14.66%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $1,010.31 | +9.27% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $6.47 | +363.68% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $63.33 | +10.53% | 4 | Oct 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $458 → $456 | $455.48 | +0.11% | 5 | Sep 25, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $18 → $22 | $20.97 | +4.91% | 5 | Sep 18, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $201.93 | -24.23% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $718.36 | +16.10% | 9 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $226.08 | -8.88% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $52.15 | +39.98% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $19.92 | +246.39% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $9.65 | +65.80% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $30.84 | +42.67% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $46.48 | +229.17% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $18.55 | -46.09% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $44.41 | +5.83% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $329.89 | -3.60% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $29.91 | -63.22% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $121.22 | -24.93% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $26.03 | +84.40% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $7.14 | +418.21% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $169.70 | +3.71% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $10.93 | +46.39% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $13.44 | +234.82% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.93 | +405.05% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $21.90 | +87.21% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $118.65 | +46.65% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $39.73 | +28.37% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $28.46 | -71.89% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $99.72 | -10.75% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $12.18 | -75.37% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $29.52 | -45.80% | 9 | Apr 2, 2020 |
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $1,010.31
Upside: +9.27%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $6.47
Upside: +363.68%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $63.33
Upside: +10.53%
Vertex Pharmaceuticals
Sep 25, 2025
Upgrades: Outperform
Price Target: $458 → $456
Current: $455.48
Upside: +0.11%
Roivant Sciences
Sep 18, 2025
Maintains: Outperform
Price Target: $18 → $22
Current: $20.97
Upside: +4.91%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $201.93
Upside: -24.23%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $718.36
Upside: +16.10%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $226.08
Upside: -8.88%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $52.15
Upside: +39.98%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $19.92
Upside: +246.39%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $9.65
Upside: +65.80%
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $30.84
Upside: +42.67%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $46.48
Upside: +229.17%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $18.55
Upside: -46.09%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $44.41
Upside: +5.83%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $329.89
Upside: -3.60%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $29.91
Upside: -63.22%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $121.22
Upside: -24.93%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $26.03
Upside: +84.40%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $7.14
Upside: +418.21%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $169.70
Upside: +3.71%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $10.93
Upside: +46.39%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $13.44
Upside: +234.82%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.93
Upside: +405.05%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $21.90
Upside: +87.21%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $118.65
Upside: +46.65%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $39.73
Upside: +28.37%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $28.46
Upside: -71.89%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $99.72
Upside: -10.75%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $12.18
Upside: -75.37%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $29.52
Upside: -45.80%